Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2025)

Xeris Biopharma Holdings' Change in Account Payables history spans 6 years, with the latest figure at -$1.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 67.36% year-over-year to -$1.7 million, compared with a TTM value of -$69000.0 through Dec 2025, up 99.28%, and an annual FY2025 reading of -$69000.0, up 99.28% over the prior year.
  • Change in Account Payables for Q4 2025 was -$1.7 million at Xeris Biopharma Holdings, down from $2.0 million in the prior quarter.
  • The five-year high for Change in Account Payables was $6.9 million in Q1 2023, with the low at -$5.2 million in Q4 2024.
  • Average Change in Account Payables over 5 years is -$75700.0, with a median of $188500.0 recorded in 2023.
  • Biggest YoY gain for Change in Account Payables was 456.57% in 2024; the steepest drop was 2090.0% in 2024.
  • Tracing XERS's Change in Account Payables over 5 years: stood at $4.4 million in 2021, then crashed by 84.15% to $690000.0 in 2022, then plummeted by 151.16% to -$353000.0 in 2023, then plummeted by 1373.94% to -$5.2 million in 2024, then surged by 67.36% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Change in Account Payables are -$1.7 million (Q4 2025), $2.0 million (Q3 2025), and -$4.4 million (Q2 2025).